Pfizer and Flynn Pharma, manufacturers of phenytoin sodium capsules which are used to treat epilepsy, have been fined a combined total of £69 million by the Competitions Appeal Tribunal (CAT) for “charging excessive prices” between 2012 and 2016.
Around 48,000 people with epilepsy in the UK depend on the drugs supplied by Flynn Pharma and Pfizer to gain seizure control.
The Competitions and Market Authority (CMA) originally imposed a fine of £90 million on the two companies following its original investigation in 2016 which concluded that they had breached competition law. It said that Pfizer and its distributor Flynn had increased prices by 2,300–2,600%, resulting in annual costs to the NHS increasing from £2m in 2012 to approximately £50m in 2013.
https://epilepsysociety.org.uk/news/epilepsy-medicine-manufacturers-fined-charging-excessive-prices